These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25213406)

  • 21. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection.
    Tite JP; Hughes-Jenkins C; O'Callaghan D; Dougan G; Russell SM; Gao XM; Liew FY
    Immunology; 1990 Oct; 71(2):202-7. PubMed ID: 2172156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.
    Saha S; Yoshida S; Ohba K; Matsui K; Matsuda T; Takeshita F; Umeda K; Tamura Y; Okuda K; Klinman D; Xin KQ; Okuda K
    Virology; 2006 Oct; 354(1):48-57. PubMed ID: 16945400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.
    Luo M; Qu X; Pan R; Zhu D; Zhang Y; Wu J; Pan Z
    Vaccine; 2011 Mar; 29(14):2561-7. PubMed ID: 21303708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM; Abdad MY; Mansfield JP; Jacobsen HK; Vind AR; Stumbles PA; Bartlett EJ
    Vaccine; 2007 Feb; 25(10):1856-67. PubMed ID: 17240000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine.
    Ju Y; Fan H; Liu J; Hu J; Li X; Li C; Chen L; Gao Q; Gao GF; Meng S
    Vaccine; 2014 May; 32(23):2703-11. PubMed ID: 24699472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence.
    Macleod MK; David A; Jin N; Noges L; Wang J; Kappler JW; Marrack P
    PLoS One; 2013; 8(4):e61775. PubMed ID: 23613928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
    Tao W; Gill HS
    Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].
    Savard C; Laliberté-Gagné MÈ; Babin C; Bolduc M; Guérin A; Drouin K; Forget MA; Majeau N; Lapointe R; Leclerc D
    Vaccine; 2012 Mar; 30(15):2535-42. PubMed ID: 22326774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
    Wu F; Yuan XY; Li J; Chen YH
    Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus.
    Hashem AM; Gravel C; Chen Z; Yi Y; Tocchi M; Jaentschke B; Fan X; Li C; Rosu-Myles M; Pereboev A; He R; Wang J; Li X
    J Immunol; 2014 Jul; 193(2):722-34. PubMed ID: 24928989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection by humoral elements independent of virus neutralization activity against an influenza virus challenge.
    Sarkadi J; Kuti D; Jankovics M; Pallinger E; Fodor K; Kis Z; Gonczol E; Visontai I; Jankovics I
    New Microbiol; 2017 Jul; 40(3):180-189. PubMed ID: 28675247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
    Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
    Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.